Skip to Main content Skip to Navigation
Master Thesis

Étude rétrospective des facteurs cliniques et biologiques associés à la réponse à l’immunothérapie dans les cancers bronchiques non à petites cellules de stade avancé

Abstract : Background. There is a significant growth in the patients population treated by immune checkpoint inhibitors (ICIs) for non-small cell lung cancer (NSCLC) but only a small proportion would benefit from these treatments. Routinely available and reproducible biomarkers for outcome after ICI therapy are strongly needed as these may influence individual treatment selection or sequence, and thus survival. Methods. We aimed to identify clinical and biological baseline factors associated with ICIs benefit in advanced NSCLC patients and compare results with literature data. Clinical characteristics, routine blood count and biochemical parameters were investigated in two French centers (Paris and Grenoble). Results. From 2014 until 2018, 152 patients were included; median age was 63 (interquartile range, 57-70) years; 114 (75%) were male; 104 (68%) were current smokers, 90 (59%) had performance status 0-1; 106 (70%) had adenocarcinoma; 129 (85%) received second-line or more ICIs. In 91 patients with available data, 44 (48%) expressed PD-L1 in ≥ 50% of tumor cells, 25 (28%) in 1-49% of cells, and 22 (24%) were PD-L1-negative. Poor baseline LIPI, combining dNLR greater than 3 and LDH greater than upper limit of normal, was observed in 16 (10.5%). After a median follow-up of 6.5 months (interquartile range 3.2-15.4), the median OS was 18 months (95% CI 11.3-not reached). They received a median of six injections (interquartile range=3-16) of ICI. ICI was an anti-PD1 in 87 % of cases, an anti-PDL1 in 5 % and a combination in 8% of cases. The incidence rate of any grade treatment-related adverse events was 37.5%. No clinical or biological factors were correlated with immunotherapy clinical benefit in NSCLC. Conclusion. Our real-life study finds results comparable to the literature in terms of survival and response but doesn’t permit to identify a marker associated with ICI’s response.
Document type :
Master Thesis
Complete list of metadatas

Cited literature [51 references]  Display  Hide  Download

https://dumas.ccsd.cnrs.fr/dumas-02293229
Contributor : Jean-Hugues Morneau <>
Submitted on : Friday, September 20, 2019 - 4:33:07 PM
Last modification on : Wednesday, July 15, 2020 - 8:58:04 AM
Long-term archiving on: : Sunday, February 9, 2020 - 2:25:22 AM

File

2019GREA5095_louvel_marie(1)(D...
Files produced by the author(s)

Identifiers

  • HAL Id : dumas-02293229, version 1

Citation

Marie Louvel. Étude rétrospective des facteurs cliniques et biologiques associés à la réponse à l’immunothérapie dans les cancers bronchiques non à petites cellules de stade avancé. Médecine humaine et pathologie. 2019. ⟨dumas-02293229⟩

Share

Metrics

Record views

54

Files downloads

31